ALG10B Inhibitors
Chemical inhibitors of ALG10B function by disrupting various steps in the glycosylation pathway, each affecting the enzyme's activity through different mechanisms. Tunicamycin, for example, prevents the initial step of N-linked glycosylation, thereby blocking the formation of dolichol-linked oligosaccharides which are essential substrates for ALG10B. Without these substrates, ALG10B cannot perform its role in adding glucose residues to the growing glycan chain. Similarly, Swainsonine and Deoxymannojirimycin target mannosidase II and mannosidases, respectively, which are enzymes that process mannose-containing glycans in the endoplasmic reticulum (ER) and Golgi apparatus. By inhibiting these enzymes, both chemicals indirectly inhibit ALG10B by preventing the maturity of the glycoproteins that ALG10B modifies. Castanospermine and Deoxynojirimycin also impair glycoprotein processing by inhibiting glucosidases responsible for trimming glucose residues, a prerequisite for the proper function of ALG10B.
Kifunensine, on the other hand, inhibits mannosidase I, which is another crucial enzyme in the processing of Asn-linked oligosaccharides, a necessary step before ALG10B's action. This results in a lack of mature substrates for ALG10B, thereby inhibiting its function. Nojirimycin and Celgosivir, both glucosidase inhibitors, disrupt the cleavage of glucose residues necessary for the proper folding and processing of glycoproteins, which is a pivotal step before ALG10B can perform its function. Salacinol and Isofagomine each target different glucosidases, but the outcome is the same: the disruption of mature glycan structures needed for ALG10B's enzymatic activity. Finally, 1-Deoxymannojirimycin, by inhibiting mannosidase, affects the oligosaccharide processing in a manner similar to that of Swainsonine and Deoxymannojirimycin, ultimately leading to an inhibition of ALG10B's functional activity. Each of these chemicals, through their distinct inhibitory actions, converges on the point of impairing ALG10B's ability to modify glycoproteins, a critical step in proper glycoprotein synthesis and processing.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation by blocking the transfer of N-acetylglucosamine to dolichol phosphate. ALG10B is involved in the glycosylation pathway, specifically in the addition of glucose residues to dolichol-linked oligosaccharides. Inhibition by Tunicamycin would prevent ALG10B from performing its function. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits mannosidase II, an enzyme involved in glycoprotein processing in the Golgi apparatus. By inhibiting upstream processes, Swainsonine would reduce the availability of properly formed glycoproteins for ALG10B to act upon, thereby functionally inhibiting ALG10B's enzymatic activity. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine is a glucosidase inhibitor that can inhibit the trimming of glucose residues in the endoplasmic reticulum. Since ALG10B's function is contingent upon the appropriate trimming of these residues, Castanospermine would impede the substrate availability for ALG10B's enzymatic action. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin acts as an α-glucosidase inhibitor. As ALG10B requires the action of glucosidases for its role in glycosylation, the inhibition of these enzymes by Deoxynojirimycin would lead to a reduction in ALG10B's functional activity due to the improper processing of glycan structures. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Deoxymannojirimycin inhibits mannosidases, which are enzymes that process mannose-containing glycans in the ER and Golgi. By inhibiting these enzymes, the glycosylation process is impaired upstream of ALG10B's action, indirectly inhibiting the function of ALG10B by preventing the formation of its glycoprotein substrates. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine is a mannosidase I inhibitor. By inhibiting this enzyme, it prevents the proper processing of Asn-linked oligosaccharides which is a precursor step before ALG10B can act. This means ALG10B's function is indirectly inhibited due to the lack of mature substrates for its enzymatic activity. | ||||||
Celgosivir | 121104-96-9 | sc-488385 sc-488385A sc-488385B | 5 mg 25 mg 100 mg | $525.00 $902.00 $2700.00 | ||
Celgosivir is an α-glucosidase I inhibitor, which would prevent the cleavage of glucose residues necessary for the proper folding and subsequent glycosylation steps that involve ALG10B, thus functionally inhibiting ALG10B due to a lack of substrate preparation. | ||||||
Isofagomine D-Tartrate | 957230-65-8 | sc-207767 sc-207767A sc-207767C sc-207767B | 5 mg 10 mg 50 mg 25 mg | $387.00 $724.00 $2015.00 $1223.00 | ||
Isofagomine inhibits β-glucosidase, another enzyme involved in glycan processing. While not directly inhibiting ALG10B, the inhibition of β-glucosidase would disrupt the formation of mature glycan structures needed for ALG10B to execute its glycosyltransferase activity, resulting in its functional inhibition. | ||||||